FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Dateline City:
KENILWORTH, N.J.
Approval Based on Results of Phase 3 Trial Evaluating Critically Ill Patients with Pneumonia; 100% of Patients Were on Mechanical Ventilation
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S.
Language:
English
Contact:
Media:
Pam Eisele
(267) 305-3558
Sarra Herzog
(908) 740-1871
Investors:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck
